Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: Which parameter at which time-point does matter?

  • Kim, Dong Hwan (Dennis); 
  • Sriharsha, Lakshmi; 
  • Jung, Chul Won; 
  • Kamel-Reid, Suzanne; 
  • Radich, Jerald P.; 
  • 외 1명
Citations

WEB OF SCIENCE

8
Citations

SCOPUS

9

초록

Early recognition of high-risk patient is important to improve long-term outcomes following imatinib therapy for chronic myeloid leukemia (CML). Some controversy surrounds the question, which of short-term response parameters at which time-point, including complete cytogenetic response (CCyR) or major molecular response (MMR) at 6 or 12 months, is the best predictor for treatment outcomes. In this comprehensive analysis, we adopted landmark analysis method, time-dependent Cox's proportional hazard model, and receiver-operating characteristics (ROC) method to analyze time-to-response parameter as predictor of long-term outcomes in 187 chronic phase (CP) CML patients. Regardless of the methods of analysis, earlier achievement of short-term response such as CCyR or MMR could predict the higher probability of achieving better interim outcome (such as treatment failure or loss of response [LOR]). Similar to the findings from other studies, our ROC analysis provided cutoff time points for MMR (18-36 months) and CCyR (6-12 months) that were the best predictors for LOR or treatment failure, which can be an indirect evidence supporting the ELN recommendation. The patient who achieves short-term response rapidly will have a lower risk of losing response or failing after imatinib therapy in CML patients. Am. J. Hematol. 85:856-862, 2010. (C) 2010 Wiley-Liss, Inc.

키워드

COMPLETE CYTOGENETIC RESPONSE; CHRONIC MYELOGENOUS LEUKEMIA; MOLECULAR RESPONSES; INTERFERON-ALPHA; MESYLATE THERAPY; RESISTANCE; DASATINIB; MECHANISMS; CYTARABINE; SURVIVAL
제목
Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: Which parameter at which time-point does matter?
저자
Kim, Dong Hwan (Dennis); Sriharsha, Lakshmi; Jung, Chul Won; Kamel-Reid, Suzanne; Radich, Jerald P.; Lipton, Jeffrey H.
DOI
10.1002/ajh.21850
발행일
2010-11
유형
Article
저널명
American Journal of Hematology
권
85
호
11
페이지
856 ~ 862